Companies / CytomX Therapeutics, Inc. / Activity
Activity — CytomX Therapeutics, Inc.
17 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | McCarthy Sean A. CEO | Sell | Common Stock | $764.1K | -119K -9.93% | 1,078,922 0.50% of shares | medium |
| Mar 17, 2026 | Belvin Marcia Executive | Sell | Common Stock | $202.3K | -31K -9.48% | 300,760 0.14% of shares | medium |
| Mar 17, 2026 | Chu Yu-Waye Executive | Sell | Common Stock | $136.7K | -21K -10.10% | 189,446 0.09% of shares | medium |
| Mar 17, 2026 | Ogden Christopher Executive | Sell | Common Stock | $124.1K | -19K -6.11% | 296,948 0.14% of shares | medium |
| Feb 2, 2026 | McCarthy Sean A. CEO | Grant | Common Stock | $0 | +210K +21.26% | 1,197,891 0.55% of shares | low |
| Feb 2, 2026 | Lester Rachael Executive | Grant | Common Stock | $0 | +20K | 20,000 <0.01% of shares | low |
| Feb 2, 2026 | Chu Yu-Waye Executive | Grant | Common Stock | $0 | +75K +55.26% | 210,725 0.10% of shares | low |
| Feb 2, 2026 | Belvin Marcia Executive | Grant | Common Stock | $0 | +60K +22.04% | 332,252 0.15% of shares | low |
| Feb 2, 2026 | Ogden Christopher Executive | Grant | Common Stock | $0 | +90K +39.78% | 316,271 0.15% of shares | low |
| Jun 17, 2026 | Meyers James R Director | Grant | Stock Option (Right to Buy) | — | +59K | 59,000 0.03% of shares | low |
| Jun 17, 2026 | Jones Elaine V Director | Grant | Stock Option (Right to Buy) | — | +59K | 59,000 0.03% of shares | low |
| Feb 2, 2026 | McCarthy Sean A. CEO | Grant | Stock Option (Right to Buy) | — | +980K | 980,000 0.45% of shares | low |
| Feb 2, 2026 | Lester Rachael Executive | Grant | Performance Stock Units (PSUs) | — | +50K | 50,000 0.02% of shares | low |
| Feb 2, 2026 | Lester Rachael Executive | Grant | Stock Option (Right to Buy) | — | +50K | 50,000 0.02% of shares | low |
| Feb 2, 2026 | Chu Yu-Waye Executive | Grant | Stock Option (Right to Buy) | — | +300K | 300,000 0.14% of shares | low |
| Feb 2, 2026 | Belvin Marcia Executive | Grant | Stock Option (Right to Buy) | — | +250K | 250,000 0.11% of shares | low |
| Feb 2, 2026 | Ogden Christopher Executive | Grant | Stock Option (Right to Buy) | — | +325K | 325,000 0.15% of shares | low |